BofA notes that Reuters reports that GoodRx (GDRX) is in discussions with the Trump administration to join the TrumpRx website though the firm doesn’t have “a strong view at this time” on the potential upside/downside from TrumpRx. The Trump administration is putting immense pressure on manufacturers and PBMs to shift completely away from list prices and toward net prices and “the popping of the gross to net bubble is a negative for GoodRx’s original business model,” the analyst tells investors. The firm, which argues that GoodRx’s future success will depend on its ability to navigate this “rapidly evolving market,” maintains an Underperform rating on GoodRx shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx, others in talks with White House to join TrumpRx, Reuters reports
- Trump Trade: U.S. could cancel additional $12B in clean energy funding
- Company tied to Trump Jr. to host summit for top drugmakers, WSJ reports
- GoodRx announces availability of Repatha
- Unusually active option classes on open October 2nd